|
gptkbp:instanceOf
|
benzodiazepine
|
|
gptkbp:ATCCode
|
N05BA11
|
|
gptkbp:brand
|
Centrax
Demetrin
Lysanxia
Prazene
Reapam
|
|
gptkbp:CASNumber
|
2955-38-6
|
|
gptkbp:cause
|
dependence
withdrawal symptoms
|
|
gptkbp:chemicalClass
|
1,4-benzodiazepine
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
severe hepatic insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (Brazil)
Schedule IV (Canada)
Schedule IV (UN)
|
|
gptkbp:developedBy
|
1960s
|
|
gptkbp:discoveredBy
|
gptkb:Warner-Lambert
|
|
gptkbp:eliminationHalfLife
|
30-150 hours
|
|
gptkbp:hasInChIKey
|
JYAMUTQHMMNRHI-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C19H17ClN2O
|
|
gptkbp:hasSMILES
|
CN1C(=O)CN=C(C2=CC=CC=C2Cl)C3=CC=CC=C13
|
|
gptkbp:hasUNII
|
U4M7X3Z5QM
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prazepam
|
|
gptkbp:IUPACName
|
7-chloro-1-methyl-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1973
|
|
gptkbp:marketedIn
|
gptkb:Belgium
gptkb:France
gptkb:Italy
gptkb:Luxembourg
gptkb:Portugal
gptkb:Switzerland
|
|
gptkbp:metabolism
|
desmethyldiazepam
|
|
gptkbp:molecularWeight
|
324.8 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:PubChem_CID
|
4857
4688
DB01581
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
muscle weakness
drowsiness
ataxia
|
|
gptkbp:soldIn
|
gptkb:United_States
|
|
gptkbp:usedFor
|
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:N05BA
|
|
gptkbp:bfsLayer
|
7
|